EG333452 inhibitors belong to a chemical class designed to specifically target and regulate the activity of certain biological molecules or pathways, commonly through the inhibition of enzyme activity or protein interactions. These inhibitors generally possess a core structure that facilitates their binding to the active site or regulatory domain of their target molecules. The molecular design often includes functional groups that enhance their affinity and selectivity towards their target, such as aromatic rings, heterocycles, or halogenated substituents. By mimicking the natural substrate or the regulatory ligand of the targeted molecule, these compounds can effectively block its function or interfere with its biological activity. The structural diversity of EG333452 inhibitors allows for variations in their binding properties and pharmacokinetic profiles, making them versatile tools in biochemical research for studying molecular pathways and enzyme functions.
Moreover, the development of EG333452 inhibitors often involves high-throughput screening of chemical libraries to identify potential lead compounds, followed by structural optimization to improve their efficacy, stability, and specificity. Structural-activity relationship (SAR) studies play a significant role in enhancing the binding capabilities of these inhibitors and in understanding the molecular interactions at play. Computational modeling and docking studies are frequently utilized to predict the binding affinity and to guide further chemical modifications. Additionally, these inhibitors are characterized by their ability to modulate biological processes in cell-based or biochemical assays, providing insights into complex cellular mechanisms and molecular functions. Overall, EG333452 inhibitors are important chemical tools that help dissect molecular pathways and can contribute to a deeper understanding of biological systems and enzymatic functions.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Histone deacetylase inhibitor disrupting chromatin structure, leading to altered accessibility of H2al1o to DNA, hindering its binding activity. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $214.00 $316.00 $418.00 | 7 | |
DNA methyltransferase inhibitor demethylating H2al1o gene, negatively impacting heterochromatin assembly, and impeding its predicted function in chromatin organization. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $226.00 $846.00 | 1 | |
Bromodomain inhibitor disrupting interactions between H2al1o and chromatin, thereby preventing its DNA binding activity and influencing heterochromatin assembly. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
HDAC inhibitor altering histone acetylation, modulating H2al1o's chromatin interactions, and potentially interfering with its predicted role in DNA binding and heterochromatin assembly. | ||||||
C646 | 328968-36-1 | sc-364452 sc-364452A | 10 mg 50 mg | $260.00 $925.00 | 5 | |
CBP/p300 HAT inhibitor impacting histone acetylation, potentially affecting H2al1o's DNA binding activity and heterochromatin assembly by altering its chromatin structure. | ||||||
BIX01294 hydrochloride | 1392399-03-9 | sc-293525 sc-293525A sc-293525B | 1 mg 5 mg 25 mg | $36.00 $110.00 $400.00 | ||
G9a histone methyltransferase inhibitor, influencing H2al1o gene methylation and potentially disrupting heterochromatin assembly, thereby modulating its predicted function. | ||||||
UNC1999 | 1431612-23-5 | sc-475314 | 5 mg | $142.00 | 1 | |
Dual inhibitor of G9a and GLP histone methyltransferases, altering H2al1o methylation patterns and potentially affecting heterochromatin assembly, thus influencing its predicted role. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $76.00 $216.00 | 101 | |
DNA cross-linking agent inducing DNA damage that may impact H2al1o's DNA binding activity, potentially interfering with its predicted function in chromatin organization. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Proteasome inhibitor affecting protein turnover, potentially influencing H2al1o levels and its involvement in heterochromatin assembly, thereby modulating its predicted function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
PI3-kinase inhibitor disrupting signaling pathways that may indirectly impact H2al1o function, influencing its predicted DNA binding activity and heterochromatin assembly. | ||||||